New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate. 16 December 2013
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected at its AGM on March 4, 2014. The board proposes Christoph Franz to be elected as Chairman of the Board. 10 December 2013
Denmark-based small molecule lead discovery company Nuevolution A/S has appointed Ton Berkien as Chief Business Officer from January 1. 9 December 2013
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member. 9 December 2013
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013
US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research. 20 November 2013
UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the board of directors with immediate effect. 20 November 2013
To support its ongoing success as a BioPharma leader, US drug major Bristol-Myers Squibb says it is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization, and has announced a series of related changes within its senior management team. 14 November 2013
AstraZeneca today announced that Marc Dunoyer has been appointed chief financial officer and will join the company board as an executive director, effective tomorrow. 31 October 2013
Merck KGaA announced today that Gerhard Schmitz will join the pharmaceutical, chemical and life science company as the new Head of Global Accounting from November 1. 30 October 2013
Mergers and acquisitions are common – 111 M&As took place in the UK in the second quarter of 2013 alone – yet there is no ‘one-size fits all’ formula to ensure smooth transitions, writes Chris Molloy, chief executive at RSA, executive search and interim management experts to the life sciences industry. 22 October 2013
US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September 10), after it announced the appointment of Brenton Saunders as its chief executive officer and president, effective from October 1. 11 September 2013
UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately. 16 December 2024
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024